204 related articles for article (PubMed ID: 21240579)
1. ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.
Narita D; Seclaman E; Ilina R; Cireap N; Ursoniu S; Anghel A
Pathol Oncol Res; 2011 Jun; 17(2):375-85. PubMed ID: 21240579
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics.
Narita D; Seclaman E; Ursoniu S; Anghel A
Acta Histochem; 2012 Feb; 114(2):131-9. PubMed ID: 21501859
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of ADAM12 gene in breast cancers.
Nariţa D; Anghel A; Seclaman E; Ilina R; Cireap N; Ursoniu S
Rom J Morphol Embryol; 2010; 51(4):669-76. PubMed ID: 21103624
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of ADAM12 and ADAM17 genes in human malignant melanoma.
Cireap N; Narita D
Pathol Oncol Res; 2013 Oct; 19(4):755-62. PubMed ID: 23645517
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.
Lendeckel U; Kohl J; Arndt M; Carl-McGrath S; Donat H; Röcken C
J Cancer Res Clin Oncol; 2005 Jan; 131(1):41-8. PubMed ID: 15565459
[TBL] [Abstract][Full Text] [Related]
6. ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.
Fröhlich C; Nehammer C; Albrechtsen R; Kronqvist P; Kveiborg M; Sehara-Fujisawa A; Mercurio AM; Wewer UM
Mol Cancer Res; 2011 Nov; 9(11):1449-61. PubMed ID: 21875931
[TBL] [Abstract][Full Text] [Related]
7. Upregulated expression of ADAM12 is associated with progression of oral squamous cell carcinoma.
Uehara E; Shiiba M; Shinozuka K; Saito K; Kouzu Y; Koike H; Kasamatsu A; Sakamoto Y; Ogawara K; Uzawa K; Tanzawa H
Int J Oncol; 2012 May; 40(5):1414-22. PubMed ID: 22267082
[TBL] [Abstract][Full Text] [Related]
8. ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins.
Fröhlich C; Klitgaard M; Noer JB; Kotzsch A; Nehammer C; Kronqvist P; Berthelsen J; Blobel C; Kveiborg M; Albrechtsen R; Wewer UM
Biochem J; 2013 May; 452(1):97-109. PubMed ID: 23458101
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of ADAM12 in human bladder cancer.
Fröhlich C; Albrechtsen R; Dyrskjøt L; Rudkjaer L; Ørntoft TF; Wewer UM
Clin Cancer Res; 2006 Dec; 12(24):7359-68. PubMed ID: 17189408
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
Stautz D; Wewer UM; Kveiborg M
PLoS One; 2012; 7(5):e37628. PubMed ID: 22662180
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
[TBL] [Abstract][Full Text] [Related]
12. ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.
Duhachek-Muggy S; Zolkiewska A
BMC Cancer; 2015 Mar; 15():93. PubMed ID: 25886595
[TBL] [Abstract][Full Text] [Related]
13. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC).
Rocks N; Paulissen G; Quesada Calvo F; Polette M; Gueders M; Munaut C; Foidart JM; Noel A; Birembaut P; Cataldo D
Br J Cancer; 2006 Mar; 94(5):724-30. PubMed ID: 16495931
[TBL] [Abstract][Full Text] [Related]
14. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of ADAM (a disintegrin and metalloproteinase) genes between human first trimester villous and extravillous trophoblast cells.
Takahashi H; Yuge K; Matsubara S; Ohkuchi A; Kuwata T; Usui R; Suzuki M; Takizawa T
J Nippon Med Sch; 2014; 81(3):122-9. PubMed ID: 24998958
[TBL] [Abstract][Full Text] [Related]
16. ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
Ma B; Ma Q; Jin C; Wang X; Zhang G; Zhang H; Seeger H; Mueck AO
Int J Clin Exp Pathol; 2015; 8(10):13279-83. PubMed ID: 26722530
[TBL] [Abstract][Full Text] [Related]
17. Assessment of gene expression in head and neck carcinoma using laser capture microdissection and real-time reverse transcription polymerase chain reaction.
Malhotra PS; Malekfzali A; Bonner RF; Juhn S; Van Waes C; Chen Z
Laryngoscope; 2004 Dec; 114(12):2123-8. PubMed ID: 15564832
[TBL] [Abstract][Full Text] [Related]
18. The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.
Ruff M; Leyme A; Le Cann F; Bonnier D; Le Seyec J; Chesnel F; Fattet L; Rimokh R; Baffet G; Théret N
PLoS One; 2015; 10(9):e0139179. PubMed ID: 26407179
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and expression analysis of ADAM12 during chicken embryonic development.
Lin J; Luo J; Redies C
Dev Growth Differ; 2010 Dec; 52(9):757-69. PubMed ID: 21158755
[TBL] [Abstract][Full Text] [Related]
20. Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype.
Li H; Duhachek-Muggy S; Dubnicka S; Zolkiewska A
Breast Cancer Res Treat; 2013 Jun; 139(3):691-703. PubMed ID: 23771733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
